<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761694</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 751-101</org_study_id>
    <nct_id>NCT02761694</nct_id>
  </id_info>
  <brief_title>ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects With Advanced Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1, dose escalation study of ARQ 751 in subjects with advanced solid
      tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other
      known actionable PTEN mutations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1, dose escalation study of ARQ 751 administered orally to
      subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K
      mutations, PTEN-null, or other known actionable PTEN mutations
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) guidelines v4.03</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The incidence of adverse events will be assessed as a measure of the safety and tolerability profile of ARQ 751</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the peak plasma concentration (Cmax) of the pharmacokinetic (PK) profile of ARQ 751</measure>
    <time_frame>Cycle 1 Day 1 (C1D1) (each cycle is 28 days) (time [t]=0,1,2,4,6,8,10,12 hours [h]), C1D2, D8, and D15 (t=0), C1D22 (t=0,1,2,4,6,8,10,12 h), C1D23, C2D1, and C2D15 (t=0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the area under the plasma concentration vs. time curve (AUC) of the pharmacokinetic (PK) profile of ARQ 751</measure>
    <time_frame>Cycle 1 Day 1 (C1D1) (each cycle is 28 days) (time [t]=0,1,2,4,6,8,10,12 hours [h]), C1D2, D8, and D15 (t=0), C1D22 (t=0,1,2,4,6,8,10,12 h), C1D23, C2D1, and C2D15 (t=0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the half life of ARQ 751 of the pharmacokinetic (PK) profile of ARQ 751</measure>
    <time_frame>Cycle 1 Day 1 (C1D1) (each cycle is 28 days) (time [t]=0,1,2,4,6,8,10,12 hours [h]), C1D2, D8, and D15 (t=0), C1D22 (t=0,1,2,4,6,8,10,12 h), C1D23, C2D1, and C2D15 (t=0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess paired tumor biopsies to determine pharmacodynamic activity of ARQ 751</measure>
    <time_frame>Tumor samples are assessed at Baseline and at any timepoint between Cycle 1 Day 15 (C1D15) and C2D1 (each cycle is 28 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in serum glucose and insulin levels to determine pharmacodynamic activity of ARQ 751</measure>
    <time_frame>Blood samples are collected on Day 1 of Cycles 1 and 2 (each cycle is 28 days) and at the End of Treatment visit, which may occur at up to 24 weeks after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of ARQ 751</measure>
    <time_frame>Up to the first 28 days (1 cycle) of therapy</time_frame>
    <description>MTD is defined as the dose level at which no more than one out of six subjects has an observable dose limiting toxicity (DLT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 after treatment with ARQ 751</measure>
    <time_frame>Tumor assessments will be performed at Baseline, every eight weeks (e.g., Cycle 3 Day 1, Cycle 5 Day 1, etc), and at the End of Treatment visit, which may occur at up to 24 weeks after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ARQ 751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ARQ 751 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day cycle. Subjects will receive treatment with ARQ 751 until unacceptable toxicity, disease progression (clinical or radiological), or another discontinuation criterion is met. It is expected that most subjects will receive between one and six cycles of ARQ 751 for a treatment period of 4 to 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 751</intervention_name>
    <description>Subjects will receive ARQ 751 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day schedule.</description>
    <arm_group_label>ARQ 751</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent granted prior to initiation of any study-specific
             procedures

          2. 18 years of age and older

          3. Histologically or cytologically documented locally advanced, inoperable or metastatic
             solid tumors with documented AKT1, 2, 3 genetic alterations, activating PI3K
             mutations, PTEN-null, or other known actionable PTEN mutations

          4. Failure to respond to standard therapy, or for whom standard or curative therapy does
             not exist, or is not tolerable.

             a. Subjects enrolled in the Expanded Cohort should have no more than 3 prior systemic
             regimens with confirmed disease progression. If the subject is refractory or has
             disease progression within 6 months of the adjuvant treatment, then the previous
             treatment should be considered as the line of treatment rather than an adjuvant
             therapy.

          5. Measurable disease

          6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          7. Archival tissue samples and/or fresh tumor biopsy samples:

               1. Subjects should agree to provide archival and/or fresh tumor biopsy samples

               2. Archival tumor samples should be collected for all enrolled subjects; if archival
                  tissue samples are not available, a recent core needle biopsy should be collected

               3. Paired, pre- and post-treatment, tumor biopsy is optional for subjects enrolled
                  in the Dose Escalation and Food-effect cohorts

               4. Paired tumor biopsy is mandatory for all subjects enrolled in the Expanded
                  cohort; subjects should agree to and be eligible for paired tumor biopsy

          8. Adequate organ function as indicated by the following laboratory values. All
             laboratory tests must be obtained within 7 days prior to the first dose of ARQ 751:

             a. Hematological i. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L ii. Platelet count
             (Plt) ≥ 100 x 109/L iii. Hemoglobin (Hb) ≥ 9 g/dL iv. International normalized ratio
             (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects receiving anticoagulant
             therapy such as Coumadin or heparin b. Renal i. Serum creatinine ≤ 1.5 x ULN or
             calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with serum creatinine
             levels &gt; 1.5 x institutional ULN c. Hepatic i. Total bilirubin ≤ 1.5 x ULN ii.
             Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN or ≤ 5 x
             ULN for subjects with known liver metastases d. Metabolic i. Glycated hemoglobin
             (HbA1c) ≤ 8%

          9. If a subject is currently receiving bisphosphonates, the subject must have received
             the bisphosphonates for at least four weeks prior to the first dose of ARQ 751.

             a. Initiation of bisphosphonates during the study may be allowed provided the subject
             completes the first cycle of treatment without any dose limiting toxicity (DLT) and
             the Investigator rules out tumor progression.

         10. Male or female subjects of child-producing potential must agree to use double-barrier
             contraceptive measures, oral contraception, or avoidance of intercourse during the
             study and for 90 days after the last dose of ARQ 751.

         11. Women of childbearing potential must have a negative serum pregnancy test during the
             Screening Period and within 48 hours of the first dose of ARQ 751. &quot;Women of
             childbearing potential&quot; is defined as sexually mature women who have not undergone a
             hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive
             months prior to the first dose of ARQ 751.

        Exclusion Criteria:

          1. Anti-cancer therapy, such as chemotherapy, immunotherapy, targeted, and
             hormonal/endocrine therapy, or investigational agents within five half-lives or four
             weeks, whichever is shorter, prior to administration of the first dose of study drug
             (five half-lives or two weeks, whichever is shorter, for orally administered drugs and
             six weeks for nitrosoureas, mitomycin C, or bevacizumab)

               1. To be eligible for study treatment, toxicity from prior treatment must recover to
                  Grade ≤ 1, except for alopecia

               2. Concurrent systemic high-dose corticosteroids when used intermittently in an
                  antiemetic regimen, for central nervous system (CNS) metastases management, or as
                  a part of the premedication regimen are allowed

               3. Concurrent standard long-term anticancer hormonal therapy with drugs including,
                  but not limited to, selective estrogen receptor modulators or
                  Gonadotropin-releasing hormone (GnRH) analogs if started at least six months
                  before the first dose of ARQ 751 is allowed

          2. Radiation therapy within four weeks prior to administration of the first dose of ARQ
             751

               1. To be eligible for study treatment, radiation therapy-related toxicity must
                  recover to Grade ≤ 1 prior to administration of the first dose of ARQ 751.

               2. Concurrent palliative radiotherapy for local pain-control may be allowed provided
                  the subject completes the first cycle of treatment, does not meet criteria of
                  progressive disease, and treated lesions will not be included in the
                  target/non-target lesion assessment.

          3. Major surgical procedure within four weeks prior to administration of the first dose
             of ARQ 751

             a. To be eligible for the study treatment, all surgical wounds must be fully healed
             and any surgery-related adverse events must recover to Grade ≤ 1.

          4. Previous treatment with AKT inhibitors (e.g., ARQ 092, MK-2206, GSK2141795, AZD5363)

          5. Unable or unwilling to swallow the complete daily dose of ARQ 751

          6. A corrected QT interval (QTc) ≥ 480 msec using the Fridericia's formula (QTcF)

          7. History of Type 1 or 2 diabetes mellitus requiring regular medication (other than oral
             hypoglycemic agents) or fasting glucose ≥ 160 mg/dL at the Pre-Study visit

          8. Significant gastrointestinal (GI) disorder(s) that could, in the opinion of the
             Investigator, interfere with the absorption, metabolism, or excretion of ARQ 751
             (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

          9. Known active CNS metastases and/or carcinomatous meningitis

             a. To be eligible for the study treatment, subjects must have stable disease ≥ 1
             month, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan,
             and have CNS metastases well controlled by low-dose steroids, anti-epileptics, or
             other symptom-relieving medications.

         10. History of myocardial infarction (MI) or New York Heart Association (NYHA) Class II-IV
             congestive heart failure within 6 months of the administration of the first dose of
             ARQ 751 (MI occurring &gt; 6 months of the first dose of ARQ 751 will be permitted);
             Grade 2 or worse conduction defect (e.g., right or left bundle branch block)

         11. Concurrent severe uncontrolled illness not related to cancer and social situation that
             would limit compliance with study requirements, including but not limited to:

               1. Psychiatric illness, substance abuse

               2. Ongoing or active known infection, including human immunodeficiency virus (HIV)
                  infection

         12. Active or history of other malignancy other than the current cancer within 2 years of
             the first dose of ARQ 751, with the exception of carcinoma in-situ of the cervix,
             basal cell carcinoma, and superficial bladder tumors curatively treated

         13. Blood transfusion or administration of growth factors within 5 days prior to a blood
             draw being used to confirm eligibility

         14. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ArQule, Inc.</last_name>
    <phone>781-994-0300</phone>
    <email>ClinicalTrials@arqule.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKT1</keyword>
  <keyword>AKT2</keyword>
  <keyword>AKT3</keyword>
  <keyword>PI3K</keyword>
  <keyword>PTEN-null</keyword>
  <keyword>solid tumors</keyword>
  <keyword>cancer</keyword>
  <keyword>ARQ 751</keyword>
  <keyword>ArQule</keyword>
  <keyword>PTEN</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

